Molecular bases of pseudo-homozygous APC resistance: The compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma

被引:29
作者
Castoldi, E
Kalafatis, M
Lunghi, B
Simioni, P
Ioannou, PA
Petio, M
Girolami, A
Mann, KG
Bernardi, F
机构
[1] Univ Ferrara, Dipartimento Biochim & Biol Mol, I-44100 Ferrara, Italy
[2] Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA
[3] Univ Padua, Sch Med, Inst Med Semeiot, Padua, Italy
[4] Cyprus Inst Neurol & Genet, Dept Mol Genet, Nicosia, Cyprus
[5] Azienda Ospedaliera Di Venere Giovanni XXIII, Serv Immunoematol & Trasfus, Bari, Italy
[6] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA
关键词
D O I
10.1055/s-0037-1615220
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pseudo-homozygous APC resistance, the condition resulting from compound heterozygosity for FV R506Q (FV Leiden) and quantitative FV deficiency, provides a natural model to study the interaction between procoagulant and anticoagulant defects. This paper reports a complete FV characterization of a pseudo-homozygous APC resistant thrombotic patient. The expression of the patient's non-leiden gene was found to be severely impaired both at the mRNA and protein levels. In particular, only FV Leiden molecules were detected in the patient's plasma by immunoblotting, which accounts for the observed marked APC resistance. Analysis of the FV cDNA obtained by reverse transcription of platelet RNA revealed that the mRNA of the non-Leiden gene was extremely reduced in amount. A PAC clone containing the whole FV gene was used to design primers for a complete FV exon scanning. A 2-bp insertion at nucleotide 3706 in the large exon 13 of the non-leiden gene, predicting a frame-shift and premature termination of protein synthesis, was identified as responsible for the FV defect. Failure to find any case of pseudo-homozygous APC resistance in a large sample (6,804) of blood donors suggests that this condition is extremely rare among normal controls and that its detection is favoured by the thrombotic risk that it may confer.
引用
收藏
页码:403 / 406
页数:4
相关论文
共 25 条
[1]  
[Anonymous], 1993, Human gene mutation
[2]   A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype [J].
Bernardi, F ;
Faioni, EM ;
Castoldi, E ;
Lunghi, B ;
Castaman, G ;
Sacchi, E ;
Mannucci, PM .
BLOOD, 1997, 90 (04) :1552-1557
[3]   MUTATION IN BLOOD-COAGULATION FACTOR-V ASSOCIATED WITH RESISTANCE TO ACTIVATED PROTEIN-C [J].
BERTINA, RM ;
KOELEMAN, BPC ;
KOSTER, T ;
ROSENDAAL, FR ;
DIRVEN, RJ ;
DERONDE, H ;
VANDERVELDEN, PA ;
REITSMA, PH .
NATURE, 1994, 369 (6475) :64-67
[4]  
Castoldi E, 1997, THROMB HAEMOSTASIS, V78, P1037
[5]   STRUCTURE OF THE GENE FOR HUMAN COAGULATION FACTOR-V [J].
CRIPE, LD ;
MOORE, KD ;
KANE, WH .
BIOCHEMISTRY, 1992, 31 (15) :3777-3785
[6]   FAMILIAL THROMBOPHILIA DUE TO A PREVIOUSLY UNRECOGNIZED MECHANISM CHARACTERIZED BY POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - PREDICTION OF A COFACTOR TO ACTIVATED PROTEIN-C [J].
DAHLBACK, B ;
CARLSSON, M ;
SVENSSON, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (03) :1004-1008
[7]   The effect of Arg(306) -> Ala and Arg(506) -> Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S [J].
Egan, JO ;
Kalafatis, M ;
Mann, KG .
PROTEIN SCIENCE, 1997, 6 (09) :2016-2027
[8]  
GEWIRTZ AM, 1986, BLOOD, V67, P1639
[9]  
GREENGARD JS, 1995, THROMB HAEMOSTASIS, V73, P1361
[10]  
GRIFFIN JH, 1995, THROMB HAEMOSTASIS, V74, P444